Physician

Ravi Patel, MD

According to 2025 Medicare claims, Ravi Patel, MD (NPI: 1366736969) practices hematology/oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Tarrant, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1033386578; TIN: 752131429) and primary practice location at 76051-3586.

Patel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 430 traditional Medicare patients, billed 106,243 HCPCS/CPT codes, and received $1,860,756 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 774 prescription claims across 137 beneficiaries totaling $976,229 in drug costs, led by Kisqali (Ribociclib Succinate). Open Payments data shows 10 records totaling $242. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $202,314 to $1,860,756. Similarly, Part D prescription costs have moved sharply higher in recent years, from $19,380 to $976,229. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.0M$2.0M2017 Medicare payment: $202,314 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $833,966 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $1,352,185 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $2,006,797 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,336,787 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $1,462,765 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $1,500,771 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,860,756 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
201712915,502$202,314
201834876,561$833,966
2019416104,719$1,352,185
2020408127,518$2,006,797
202140677,005$1,336,787
202241690,664$1,462,765
202345997,037$1,500,771
2024430106,243$1,860,756

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$528K$1.1M2015 Drug cost: $19,380 (USD; Tot_Drug_Cst)2016 Drug cost: $1,607 (USD; Tot_Drug_Cst)2017 Drug cost: $85,299 (USD; Tot_Drug_Cst)2018 Drug cost: $98,117 (USD; Tot_Drug_Cst)2019 Drug cost: $378,869 (USD; Tot_Drug_Cst)2020 Drug cost: $629,626 (USD; Tot_Drug_Cst)2021 Drug cost: $746,044 (USD; Tot_Drug_Cst)2022 Drug cost: $1,056,395 (USD; Tot_Drug_Cst)2023 Drug cost: $963,687 (USD; Tot_Drug_Cst)2024 Drug cost: $976,229 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201540105$19,380
20163790$1,607
201746117$85,299
201860344$98,117
2019102574$378,869
2020120623$629,626
2021129653$746,044
2022132670$1,056,395
2023147757$963,687
2024137774$976,229

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more159250$64
82728Ferritin (blood protein) level92157$13
80053Blood test, comprehensive group of blood chemicals194584$10
36415Insertion of needle into vein for collection of blood sample149421$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count195619$8

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
KisqaliRibociclib Succinate11392$259,744
RevlimidLenalidomide12336$210,674
CalquenceAcalabrutinib Maleate13390$182,909
ErleadaApalutamide12360$179,142
EliquisApixaban602,460$46,209

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.10$242ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Ravi Patel, MD?

Tedicare shows public-source Medicare data for Ravi Patel, MD (NPI 1366736969), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ravi Patel, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ravi Patel, MD?

Ravi Patel, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1033386578) in the available physician profile data.

Does Ravi Patel, MD have Open Payments data?

Ravi Patel, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.